Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,873 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06720727 | Craniospinal Irradiation in Histone AlteRed Midline Glioma(CHARM) | recruiting | N/A | 32 | Tata Memorial CentreOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06782984 | Drug Response Testing and Repurposing Using Glioblastoma Organoid | recruiting | — | 150 | Chungnam National University HospitalOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06703255 | A Phase 2 Study of HX301 in Patients with High-grade Giloma | recruiting | Phase 1 / Phase 2 | 72 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06679816 | Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors | recruiting | Phase 4 | 882 | Beijing Tiantan HospitalOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT05641441 | Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma | recruiting | — | 258 | University Hospital, GenevaOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05528939 | Feasibility/Acceptability of Attentional-Control Training in Survivors(FAACTS) | recruiting | N/A | 50 | Children's National Research InstituteOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06757153 | Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients | recruiting | Early Phase 1 | 15 | Zhongnan HospitalOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06684639 | A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma | recruiting | Early Phase 1 | 30 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06740097 | Feasibility of Aspirate Tissue Monitoring in Neuro-oncological Surgery(ATM GBM INT) | recruiting | N/A | 50 | Kuopio University HospitalOTHER | 2 | Dec 18, 2024 | clinicaltrials |
| NCT06740955 | Hypofractionated Radiotherapy | recruiting | N/A | 420 | The First Hospital of Jilin UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06737250 | NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL(POTENTIAL-P) | recruiting | Phase 2 | 33 | NOBO MedicineINDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT02824731 | Comparison of Proton and Photon Radiotherapy of Brain Tumors (ProtoChoice-Hirn) | recruiting | N/A | 555 | Technische Universität DresdenOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06736470 | Surgical Suction Aspirates Fluorescence Measurement(ATM GBM) | recruiting | — | 25 | Kuopio University HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06116903 | Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes(ExoGLIE) | recruiting | N/A | 60 | University Hospital, LimogesOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT05254197 | SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)(SOLOMON) | recruiting | — | 3,000 | Seoul National University HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06172595 | FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma(FET PET in HGG) | recruiting | Phase 2 | 22 | Singapore General HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05768919 | Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | recruiting | Phase 1 / Phase 2 | 30 | SignPath Pharma, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06161610 | Recurrent High Grade Glioma Treated by LITT(REGALITT) | recruiting | N/A | 135 | Beijing Tiantan HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT04648462 | Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology | recruiting | — | 1,500 | Maastricht Radiation OncologyOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06705036 | Differential Study of Invasive Pituitary Adenomas in the Sellar and Cavernous Sinus Regions | recruiting | — | 20 | Shanghai Zhongshan HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT03745534 | Cochlear Implantation After Gamma Knife Radiosurgery with EABR and Correlation to Postoperative Hearing Results - a Pilot Study | recruiting | — | 8 | Christoph ArnoldnerOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT03745560 | Intraoperative EABR for Decision Making | recruiting | — | 15 | Christoph ArnoldnerOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT04233788 | Metabolic Characterization of Space Occupying Lesions of the Brain(FASTMRSI) | recruiting | — | 55 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06362304 | 99mTc-CNDG SPECT/CT in Brain Tumors | recruiting | N/A | 30 | Peking Union Medical College HospitalOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06702826 | Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases | recruiting | Phase 2 | 20 | Rongrong ZhouOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06444607 | Hereditary Pheochromocytoma Assessment of Tumour Immunologies(HEPHESTOS) | recruiting | — | 200 | Radboud University Medical CenterOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06160206 | Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | recruiting | Phase 2 | 134 | Academic and Community Cancer Research UnitedOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06043765 | Reducing Cognitive Impairment in Glioma with Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training(TRUE-GRIT) | recruiting | N/A | 16 | Linda DouwOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05826158 | 18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma | recruiting | N/A | 25 | Rigshospitalet, DenmarkOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04070040 | Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) | recruiting | Phase 2 | 21 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04267978 | Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas | recruiting | Phase 2 | 109 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04501705 | Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults | recruiting | N/A | 29 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04501718 | Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children | recruiting | Phase 2 | 44 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05278715 | Modified CV Regimen in Optic Pathway Glioma | recruiting | Phase 2 | 75 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06180434 | Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas(SOPRANO) | recruiting | — | 320 | Erasmus Medical CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06623565 | Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques(NEXTFRONTIER) | recruiting | N/A | 30 | Amsterdam UMC, location VUmcOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06282224 | Application of Augmented Reality Neuronavigation in Transnasal Endoscopic Skull Base Surgery | recruiting | N/A | 10 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06620055 | Development of an Artificial Intelligence Model for Optimising Therapy in Gliomas Gliomas(GLIO-AI) | recruiting | — | 164 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06613295 | Separation Surgery Followed by Stereotactic Ablative Body Radiotherapy (SABR) Versus SABR Alone for Spinal Metastases(SABR-MESCC) | recruiting | N/A | 128 | Cancer Research AntwerpOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06610851 | Monitoring of Patients With Low-grade Gliomas Using Circulating miRNA(GLIBAMIR) | recruiting | — | 20 | University Hospital, CaenOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT05996432 | Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy | recruiting | Early Phase 1 | 48 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT05512403 | Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics(KING) | recruiting | Phase 3 | 88 | Central Hospital, Nancy, FranceOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06112509 | Evolution of Vestibular Function After Treatment of a Vestibular Schwannoma by Gamma-knife Radio-surgery(EVERS) | recruiting | N/A | 20 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06587022 | Delineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors(ST-SBRT) | recruiting | — | 500 | Peking University Third HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06595186 | JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) | recruiting | Phase 2 | 25 | JenKem Technology Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06314607 | Genetic and Molecular Characterization of Nervous System Lesions(ONCONEUROTEK 2) | recruiting | — | 10,000 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT06501391 | Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis | recruiting | Phase 2 | 54 | Fudan UniversityOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06574698 | Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma | recruiting | — | 64 | Guangzhou Women and Children's Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06572475 | USPIO Enhanced MR Imaging in CNS Tumours (UMIC)(UMIC) | recruiting | N/A | 17 | Northern Care Alliance NHS Foundation TrustOTHER | 1 | Aug 27, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 20, 2025source: clinicaltrials